Skip to main content

Market Overview

Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook

Share:
Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook

Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating the consensus of $1 billion.

The company reported adjusted EPS of $2.72, beating the Wall Street estimate of $2.37.

Acquisitions contributed 0.2% to consolidated third-quarter revenue growth. The impact of foreign currency translation benefited reported revenue growth by 1.4%. The divestiture of the Avian Vaccine business in December 2022 reduced reported revenue growth by 1.9%. 

Excluding the effect of these items, organic revenue growth of 4.1% was driven primarily by the Discovery and Safety Assessment and the Research Models and Services business segments.

"We were pleased that our third-quarter financial results exceeded our expectations and that some early signs of more favorable demand trends began to emerge, such as a sequential improvement in the Safety Assessment cancellation rate," CEO James Foster said. "However, we also experienced continued pressure from current client spending patterns, which began to have a discernable impact on the RMS segment and our Microbial Solutions business in the third quarter."

Guidance: Charles River Laboratories expects FY23 revenue growth of 2.5%–3.5% versus 2.5%–4.5% expected earlier.

The Wilmington, Massachusetts-based company forecasts adjusted EPS of $$10.50 – $10.70 compared to the prior guidance of $10.30–$10.90 and consensus of $10.56.

Price Action: CRL shares are up 0.30% at $183.36 on the last check Wednesday.

Now Read: Endangered Horseshoe Crabs Vital In Medical Research, Charles River Lab Commits To Enhanced Protection

 

Related Articles (CRL)

View Comments and Join the Discussion!

Posted-In: Briefs life sciencesEarnings News Guidance Health Care Top Stories General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com